Anita Giobbie-Hurder

Jun 2, 2023 | nature.com | Priscilla K Brastianos |Anita Giobbie-Hurder |Beth Overmoyer |Sara M. Tolaney |Erica L. Mayer

AbstractBrain metastases (BMs) are an emerging challenge in oncology due to increasing incidence and limited treatments. Here, we present results of a single-arm, open-label, phase 2 trial evaluating intracranial efficacy of pembrolizumab, a programmed cell death protein 1 inhibitor, in 9 patients with untreated BMs (cohort A) and 48 patients with recurrent and progressive BMs (cohort B) across different histologies.